A., McLaggan, D., Nikolaev, Y., Ness, L
405 The SURMOUNT-2 trial, a separate phase III trial conducted in seven countries, randomized 938 adults with type 2 diabetes and a BMI 27 kg/m 2 to receive tirzepatide (10 mg or 15 mg) or placebo once-weekly for 72 weeks
The answer lies in the format itself - the spray mechanism supports micro-controlled delivery, allowing labs to design structured exposure schedules with reduced variability
However, its important to follow proper protocols and consult with healthcare professionals.
Obesity and Metabolism, 12(1), 16-19
(Hint: These solutions can be supported either through an organizations current pharmacy benefit manager or through a full carve-out for GLP-1 weight loss medications.) Join us in pioneering a future where better health is accessible to all